Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-7613Central Research Institute for Epidemiology13628ArticlesСтатьиReview ArticleDEVELOPMENT OF VACCINE PREPARATION FOR UROGENITAL CHLAMYDIOSIS PROPHYLAXISРАЗРАБОТКА ВАКЦИННЫХ ПРЕПАРАТОВ ДЛЯ ПРОФИЛАКТИКИ УРОГЕНИТАЛЬНОГО ХЛАМИДИОЗАKorolevaE. AКоролеваЕ. АZigangirovaN. AЗигангироваН. АGamaleya Research Institute of Epidemiology and MicrobiologyНИИ эпидемиологии и микробиологии им. Н.Ф.Гамалеи15122011886NO6 (2011)№6 (2011)11412309062023Copyright ©; 2011, Koroleva E.A., Zigangirova N.A.Copyright ©; 2011, Королева Е.А., Зигангирова Н.А.2011Koroleva E.A., Zigangirova N.A.Королева Е.А., Зигангирова Н.А.https://creativecommons.org/licenses/by/4.0https://microbiol.crie.ru/jour/article/view/13628

Chlamydia trachomatis is one of the most widespread bacterial pathogens in the world that is transmitted sexually. Thereby a development of vaccine preparation for therapy and prophylaxis of infections caused by C.trachomatis is an actual topic of scientific research across the entire world. These vaccines could be used for both prophylaxis and therapy of already established chlamydia infection and, respectively, reduce the risk of chronic condition and prevent the spread of pathogen in the population. Features of chlamydia biology that are associated with obligate intracellular parasitism and im-munopathologic state induced by this agent significantly complicate developments in this field. Currently a vaccine preparation that has reached clinical trials does not exist.

Chlamydia trachomatis - один из самых распространенных в мире бактериальных патогенов, передающийся половым путем. В связи с этим, разработка вакцинного препарата для лечения и профилактики инфекций, вызываемых C.trachomatis, - актуальное направление научных исследований во всем мире. Такие вакцины могут использоваться как для профилактики, так и для лечения уже установившейся хламидийной инфекции и, соответственно, снижать риск развития хронических состояний и препятствовать распространению патогена в популяции. Особенности биологии хламидий, связанные с облигатным внутриклеточным паразитированием, и индуцируемые возбудителем иммунопатологические состояния серьезно осложняют разработки в этой области. В настоящее время вакцинного препарата, перешедшего на стадию клинических испытаний, не существует.

Chlamydia trachomatisurogenital chlamydiosisChlamydia trachomatisvaccine preparationsурогенитальный хламидиозвакцинные препаратыВасильев М.М. Хламидийная инфекция. Проблема антибиотикорезистентности. Вест. дерматол. и венерол. 2003, 3: 1821.Лебедев В.А. Урогенитальный хламидиоз. Вопр. гинекологии, акушерства и перинатологии. 2002, 1(2): 25-30.Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines-US perspective. Vaccine. 2002, 20 (3): 18-23.Berry L.J., Hickey D.K., Skelding K.A. et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infection Immun. 2004, 2: 1019-1028.Brumham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature Rev. Immunology. 2005, 5: 149-161.Brunham R.C., Kimani J., Bwayo J. et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J. Infect. Dis. 1996, 173: 950-956.Carabeo R.A., Grieshaber S.S., Fischer E. et al. Chlamydia trachomatis induces remodeling ofthe actin cytoskeleton during attachment and entry into HeLa cells. Infect. Immun. 2002, 7: 3793-3803.Caro M.R., Buendia A.J., Ortega N. et al. Ovine enzootic abortion (OEA): Antibody response in vaccinated sheep compared to naturally infected sheep. Veterinary Research Communications. 2005, 1: 151-156.Caro M.R., Buendia A.J., Ortega N. et al. Influence of the Th2 immune response established by Nippostrongylus brasiliensis infection on the protection offered by different vaccines against Chlamydophila abortus infection. Veterinary Res. Comm. 2001, 1: 51-59.Darvile T., Hiltke T.J. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J. Infect. Dis. 2010, 201 (2): 114-125.de la Maza M.A., de la Maza L.M. A new computer model for estimating the impact ofvaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine. 1995, 13: 119127.Delevoye C., Nilges M., Dautry-Varsat A. et al. Conservation of the biochemical properties of IncA from Chlamydia trachomatis and Chlamydia caviae: oligomerization of IncA mediates interaction between facing membranes. J. Biol. Chem. 2004, 279: 46896-46906.Eko F.O., He Q., Brown T. et al. A Novel Recombinant Multisubunit Vaccine against Chlamydia. J. Immunology. 2004, 173: 3375-3382.Fadel S., Eley A. Differential glycosaminoglycan binding of Chlamydia trachomatis OmcB protein from serovars E and LGV. J. Med. Microbiol. 2008, 57: 1058-1061.Fadel S., Eley A. Chlamydia trachomatis OmcB protein is a surface-exposed glycosaminoglycan-dependent adhesion. Med. Microbiol. 2007, 56: 15-22.Findlay H.E., McClafferty H., Ashley R.H. Surface expression, single-channel analysis and membrane topology of recombinant Chlamydia trachomatis major outer membrane protein. BMC Microbiol. 2005, 5: 5-20.Grayston J.T., Wang S.P., Yeh L.J. et al. Importance ofreinfection in the pathogenesis of trachoma. Rev. Infect. Dis. 1985, 7: 717-725.Guifeng S., Pal S., Weiland J. et al. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009, 27 (36): 50205025.Gupta R., Srivastava P., Vardhan H. et al. Host immune responses to chlamydial inclusion membrane proteins B and C in Chlamydia trachomatis infected women with or without fertility disorders. Reprod. Biol. Endocrinol. 2009, 7: 38.Hayes F., Lubetzki S.A. and Sherratt D.J. Salmonella typhimurium specifies a circular chromosome dimer resolution system which is homologous to the Xer site-specific recombination system of Escherichia coli. Gene. 1997, 198: 105-110.Jewett T., Fischer E.R., Mead D.J. et al. Chlamydial TARP is a bacterial nucleator of actin. PNAS. 2006, 42: 15599-15604.Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines. 2003, 2: 305-315.Longbottom D. Chlamydial vaccine development. J. Med. Microbiol. 2003, 52: 537-540.Moelleken K., Hegemann J.H. The Chlamydia outer membrane protein OmcB is required for adhesion and exhibits biovar-specific differences in glycosaminoglycan binding. Mol. Microbiol. 2008, 2: 403419.Morrison R.P., Caldwell H.D. Immunity to murine genital chlamydial infection. Infect. Immun. 2002, 70: 2741-2751.Morrison S.G., Su H., Caldwell H.D. et al. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells. Infect. Immun. 2000, 68: 69796987.Murdin A.D., Dunn P., Sodoyer R. et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis. 2000, 181 (3): 544-551.Murdin A.D., Su H., Klein M.H. et al. Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis-neutralizing antibodies. Infect. Immun. 1995, 63 (3): 1116-1121.Murthy A.K, Guentzel M.N, Zhong G. et al. Chlamydial protease-like activity factor-insights into immunity and vaccine development. J. Reprod. Immunol. 2009, 83 (1 - 2): 179-184.Murthy A.K., Chambers J.P., Meier P.A. et al. Intranasal vaccination with a secreted chlamydial hrotein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect. Immun. 2007, 75 (2): 666-676.Mutwiri G., Gerdts V., Lopez M. et al. Innate immunity and new adjuvants. Rev. Sci. Tech. Off. Int. Epiz. 2007, 26 (1): 147156.Ohshige K. Behavioural and serological human immunodeficiency virus risk factors among female commercial sex workers in Cambodia. Int. J. Epidemiology. 2000, 29: 344-354.Petrovsky N., Aguilar J.C. Vaccine adjuvants: Current state and future trends. Immunology and Cell Biology. 2004, 82: 488-496.Roberts T.E., Robinson S., Barton P. et al. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Trans. Infect. 2006, 82: 193-200.Rothfuchs A.G., Kreuger M.R., Wigzell H. et al. Macrophages, CD4(+) or CD8(+) cells are each sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-gamma. J. Immunol. 2004, 172: 24072415.Rottenberg M.E., Gigliotti-Rothfuchs A., Wigzell H. The role of IFN-gamma in the outcome of chlamydial infections. Curr. Op. Immunology. 2002, 14: 444-451.Smith J.S, Bosetti C., Munoz N. et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int. J. Cancer. 2004, 111: 431-439.Shaw J., Grund V., Durling L. et al. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2 rather than type 1 immune response that is not protective. Infect. Immun. 2002, 70: 10971105.Stephens R.S. Chlamydial genomics and vaccine antigen discovery. J. Infect. Dis. 2000, 181: 521-523.Su H., Messer R., Whitmire W. et al. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae. J. Exp. Med. 1998, 188: 809818.Su Н., Raymond L., Rockey D.D. et al. A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc. Nat. Acad. Sci. 1996, 20: 1114311148.Suna H.X., Xiea Y, Yec Y. -P. Advances in saponin-based adjuvants. Vaccine. 2009, 27: 1787-1796.Tan C., Hsia R.-C., Shou H. et al. Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. Infect. Immun. 2009, 77: 32183226.Vajdy M., Lycke N.Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology. 1992, 75 (3): 488-492.Wehrl W., Brinkmann V., Jungblut P.R. From the inside out-processing of the Chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells. Mol. Microbiol. 2004, 2: 319-334.Zhong G. at al. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine. 2009, 27 (22): 2967-2980.Zhong G., Fan P., Ji H. et al. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J. Exp. Med. 2001, 8: 935-942.Zhong G., Liu L., Fan T. et al. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J. Exp. Med. 2000, 191: 1525-1534.Zhong G., Fan T., Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 1999, 189: 1931-1938.Zhou J., Qiu C., Cao X.-A., Guozhen L. Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chicks. Vaccine. 2007, 34: 6367-6372.